CL2012002203A1 - Composicion farmaceutica bucal solida que contiene agomelatina y uno o mas excipientes elegidos entre diluyentes, aglutinantes, agentes de dispersion, lubricantes, agentes de recubrimientos, platificantes aromatizantes, contra-irritantes y edulciorantes, util en tretamientos de depresion, trsatornos bipolares, entre otros. - Google Patents

Composicion farmaceutica bucal solida que contiene agomelatina y uno o mas excipientes elegidos entre diluyentes, aglutinantes, agentes de dispersion, lubricantes, agentes de recubrimientos, platificantes aromatizantes, contra-irritantes y edulciorantes, util en tretamientos de depresion, trsatornos bipolares, entre otros.

Info

Publication number
CL2012002203A1
CL2012002203A1 CL2012002203A CL2012002203A CL2012002203A1 CL 2012002203 A1 CL2012002203 A1 CL 2012002203A1 CL 2012002203 A CL2012002203 A CL 2012002203A CL 2012002203 A CL2012002203 A CL 2012002203A CL 2012002203 A1 CL2012002203 A1 CL 2012002203A1
Authority
CL
Chile
Prior art keywords
diluents
binders
useful
pharmaceutical composition
composition containing
Prior art date
Application number
CL2012002203A
Other languages
English (en)
Inventor
Tharrault Francois
Poirier Cecile
Fonknechten Gilles
Manuel Pean Jean
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46603817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002203(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2012002203A1 publication Critical patent/CL2012002203A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica bucal sólida que contiene agomelatina y al menos un excipiente elegido entre diluyentes, aglutinantes, entre otros, la cual permite obtener una liberación lenta del principio activo y una biodisponibilidad absoluta superior al 25%, útil para el tratamiento de la depresión mayor, trastornos del sueño, entre otros.
CL2012002203A 2011-08-10 2012-08-08 Composicion farmaceutica bucal solida que contiene agomelatina y uno o mas excipientes elegidos entre diluyentes, aglutinantes, agentes de dispersion, lubricantes, agentes de recubrimientos, platificantes aromatizantes, contra-irritantes y edulciorantes, util en tretamientos de depresion, trsatornos bipolares, entre otros. CL2012002203A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1102500A FR2978916B1 (fr) 2011-08-10 2011-08-10 Composition pharmaceutique solide pour administration buccale d'agomelatine

Publications (1)

Publication Number Publication Date
CL2012002203A1 true CL2012002203A1 (es) 2012-11-23

Family

ID=46603817

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002203A CL2012002203A1 (es) 2011-08-10 2012-08-08 Composicion farmaceutica bucal solida que contiene agomelatina y uno o mas excipientes elegidos entre diluyentes, aglutinantes, agentes de dispersion, lubricantes, agentes de recubrimientos, platificantes aromatizantes, contra-irritantes y edulciorantes, util en tretamientos de depresion, trsatornos bipolares, entre otros.

Country Status (29)

Country Link
US (1) US20130041040A1 (es)
EP (1) EP2556824A1 (es)
JP (1) JP2013040170A (es)
KR (1) KR20130018156A (es)
CN (1) CN102949360A (es)
AP (1) AP2012006411A0 (es)
AR (1) AR087490A1 (es)
AU (1) AU2012211406A1 (es)
BR (1) BR102012020320A2 (es)
CA (1) CA2784853A1 (es)
CL (1) CL2012002203A1 (es)
CO (1) CO6620024A1 (es)
CR (1) CR20120409A (es)
CU (1) CU20120115A7 (es)
EA (1) EA201201007A1 (es)
EC (1) ECSP12012088A (es)
FR (1) FR2978916B1 (es)
GT (1) GT201200237A (es)
MD (1) MD20120062A3 (es)
MX (1) MX2012009148A (es)
NI (1) NI201200130A (es)
PE (1) PE20130381A1 (es)
PH (1) PH12012000220A1 (es)
RU (1) RU2014108915A (es)
SG (1) SG188042A1 (es)
TW (1) TW201311233A (es)
UY (1) UY34238A (es)
WO (1) WO2013021139A1 (es)
ZA (1) ZA201205978B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114028335A (zh) * 2021-12-24 2022-02-11 山东京卫制药有限公司 一种阿戈美拉汀溶液鼻喷剂及其应用
CN117562862A (zh) * 2023-08-29 2024-02-20 宝利化（南京）制药有限公司 一种阿戈美拉汀的固体药物组合物及其制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
JP2642354B2 (ja) * 1987-06-11 1997-08-20 株式会社 三和化学研究所 徐放性バッカル剤の製法
US5004601A (en) * 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH04169522A (ja) * 1990-11-01 1992-06-17 Shin Etsu Chem Co Ltd 徐放性錠剤およびその製造方法
TR199802305T2 (xx) * 1996-05-13 2002-06-21 Norvartis Consumer Health S.A. Yanaktan uygulama y�ntemi.
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
FR2823974B1 (fr) * 2001-04-25 2004-10-15 Pf Medicament Pastille medicamenteuse a liberation lente du principe actif
DE60211186T2 (de) 2001-09-19 2007-01-18 Merck Patent Gmbh Neue verwendung substituierter aminomethylchromane
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
US7579442B2 (en) * 2002-04-16 2009-08-25 Ocugenics, LLC Method for stromal corneal repair and refractive alteration
JP4251907B2 (ja) 2003-04-17 2009-04-08 シャープ株式会社 画像データ作成装置
GB0320854D0 (en) * 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2884714B1 (fr) * 2005-04-20 2011-05-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
KR20060122027A (ko) 2005-05-25 2006-11-30 엘지전자 주식회사 콘텐츠용 이동통신 단말기
FR2889521B1 (fr) 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889523B1 (fr) 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889522B1 (fr) 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2890562B1 (fr) * 2005-09-09 2012-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
CN100376765C (zh) 2005-10-28 2008-03-26 中国科学院工程热物理研究所 一种用于多级叶轮机的三维时序效益最大化方法
FR2894475B1 (fr) * 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
EP2029136A4 (en) * 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc TREATMENT FOR DEPRESSION DISEASES
WO2007137224A2 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Method of treatment
FR2908995B1 (fr) * 2006-11-24 2009-02-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis
JP5590676B2 (ja) * 2007-09-13 2014-09-17 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｐｅｒ３ｖｎｔｒ遺伝子型に基づく睡眠パラメータ及び睡眠誘導化合物に対する応答の予測
WO2009137531A2 (en) * 2008-05-06 2009-11-12 Somaxon Pharmaceuticals, Inc. Compositions and methods related to action of low dosages of doxepin on the h1 and 5-ht2a receptors
CN101481321B (zh) 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN101585779B (zh) 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN101955440B (zh) 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
CN101991577A (zh) * 2009-08-19 2011-03-30 北京利乐生制药科技有限公司 新型精神类药物组合物
CN102050755B (zh) * 2009-10-29 2014-11-05 重庆医药工业研究院有限责任公司 阿戈美拉汀的晶型及其制备方法
CN102050756A (zh) 2009-11-09 2011-05-11 北京利乐生制药科技有限公司 阿戈美拉汀新晶型及其制备方法
CN101781226B (zh) 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN102190595A (zh) 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102190594A (zh) 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
CN101870662B (zh) 2010-05-21 2013-03-20 中山大学 结晶型阿戈美拉汀溶剂化物及其制备方法
WO2012046253A2 (en) 2010-10-08 2012-04-12 Msn Laboratories Limited Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms
CN102030673B (zh) 2010-11-24 2014-04-23 威海迪素制药有限公司 一种阿戈美拉汀新晶型及制备方法
CN101991559B (zh) * 2010-11-25 2012-04-18 天津市汉康医药生物技术有限公司 一种稳定的阿戈美拉汀胶囊药物组合物
CN102206864B (zh) 2011-04-13 2012-10-03 吉林省博大伟业制药有限公司 阿戈美拉汀的ⅵ晶型单晶及混合晶型和制备方法
CN102503886B (zh) 2011-10-11 2013-09-11 中山大学 阿戈美拉汀-异烟碱共晶及其组合物和制备方法
CN102432490A (zh) 2011-11-02 2012-05-02 江西施美制药有限公司 一种阿戈美拉汀晶型d及其制备方法

Also Published As

Publication number Publication date
RU2014108915A (ru) 2015-09-20
MD20120062A3 (ro) 2016-06-30
US20130041040A1 (en) 2013-02-14
EP2556824A1 (fr) 2013-02-13
JP2013040170A (ja) 2013-02-28
CR20120409A (es) 2013-05-16
PH12012000220A1 (en) 2014-03-03
FR2978916A1 (fr) 2013-02-15
AU2012211406A1 (en) 2013-02-28
ZA201205978B (en) 2013-05-29
ECSP12012088A (es) 2014-03-31
KR20130018156A (ko) 2013-02-20
BR102012020320A2 (pt) 2013-10-29
CN102949360A (zh) 2013-03-06
PE20130381A1 (es) 2013-04-06
AP2012006411A0 (en) 2012-08-31
CO6620024A1 (es) 2013-02-15
EA201201007A1 (ru) 2013-03-29
TW201311233A (zh) 2013-03-16
CA2784853A1 (fr) 2013-02-10
MD20120062A2 (en) 2013-02-28
GT201200237A (es) 2014-08-11
MX2012009148A (es) 2013-02-21
NI201200130A (es) 2013-02-05
CU20120115A7 (es) 2012-10-15
FR2978916B1 (fr) 2013-07-26
NZ601713A (en) 2014-01-31
WO2013021139A1 (fr) 2013-02-14
UY34238A (es) 2013-02-28
SG188042A1 (en) 2013-03-28
AR087490A1 (es) 2014-03-26

Similar Documents

Publication Publication Date Title
CY1121675T1 (el) Διαμορφωτες υποδοχεων nmdα σπeipο-λακταμης και χρησεις αυτων
CL2012003421A1 (es) Compuestos derivados de 3-amino-n-(4-carbamoilpiridin-3-il)(aril/heteroaril)-2-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad del snc, oncologica, entre otras. pct fase nacional
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
PH12014501702A1 (en) Imidazopyrrolidinone compounds
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
PE20200175A1 (es) Formas de dosificacion de ruxolitinib de liberacion sostenida
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
AR088936A1 (es) Formulaciones farmaceuticas
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
CL2014000210A1 (es) Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
ECSP13013012A (es) Análogos del ácido epoxieicosatrienoicos y métodos de preparación
BR112014009580A2 (pt) composição farmacêutica de omeprazol
MX374938B (es) Un método para el tratamiento de trastornos del movimiento con befiradol.
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
MX379454B (es) Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.
CY1120545T1 (el) Συνθεση για τη θεραπεια της διαταραχης μειωμενης σεξουαλικης επιθυμιας
CO6602160A2 (es) Terapia de b12 oral
UA112981C2 (uk) Варіант людського gdnf
BR112015010808A2 (pt) pastilha medicamentosa à base de ibuprofeno sódico di-hidratado
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза